Purpose: BRAF mutations are grouped in activating RASindependent signaling as monomers (class 1-V600E) or as dimers (class 2-codons 597/601), and RAS-dependent with impaired kinase activity (class 3-codons 594/596). Although clinical, pathologic, and molecular features of V600EBRAFmutated metastatic colorectal cancer (mCRC) are well known, limited data are available from the two other classes. Experimental Design: Data from 117 patients with BRAF (92 class 1, 12 class 2, and 13 class 3)-mutated mCRC were collected. A total of 540 BRAF wt mCRCs were included as control. IHC profiling was performed to determine the consensus molecular subtypes (CMS), cytokeratin 7/20 profiles, tumor-infiltrating lymphocyte infiltration, and BM1/BM2 categorization. Overall survival (OS) and progression-free survival were evaluated by Kaplan-Meier and log-rank test. Results: Class 3 BRAF-mutated mCRC was more frequently left sided (P = 0.0028), pN0 (P = 0.0159), and without peritoneal metastases (P = 0.0176) compared with class 1, whereas class 2 cases were similar to class 1. Hazard ratio for OS, as compared with BRAF wt, was 2.38 [95% confidence interval (CI), 1.61-3.54] for class 1, 1.90 (95% CI, 0.85-4.26) for class 2, and 0.93 (95% CI, 0.51-1.69) for class 3 (P < 0.0001). Class 2 and 3 tumors were all assigned to CMS2-3. A higher median CD3/CD8-positive lymphocyte infiltration was observed in BRAF-mutated class 2 (P = 0.033) compared with class 3 cases. Conclusions: For the first time, different clinical and pathologic features and outcome data were reported according to the three BRAF mutation classes in mCRC. Specific targeted treatment strategies should be identified in the near future for such patients.

Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization / Schirripa, M.; Biason, P.; Lonardi, S.; Pella, N.; Simona Pino, M.; Urbano, F.; Antoniotti, C.; Cremolini, C.; Corallo, S.; Pietrantonio, F.; Gelsomino, F.; Cascinu, S.; Orlandi, A.; Munari, G.; Malapelle, U.; Saggio, S.; Fontanini, G.; Rugge, M.; Mescoli, C.; Lazzi, S.; Bonetti, L. R.; Lanza, G.; Dei Tos, A. P.; De Maglio, G.; Martini, M.; Bergamo, F.; Zagonel, V.; Loupakis, F.; Fassan, M.. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 25:13(2019), pp. 3954-3961. [10.1158/1078-0432.CCR-19-0311]

Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization

Gelsomino F.;Cascinu S.;Bonetti L. R.;Lanza G.;
2019

Abstract

Purpose: BRAF mutations are grouped in activating RASindependent signaling as monomers (class 1-V600E) or as dimers (class 2-codons 597/601), and RAS-dependent with impaired kinase activity (class 3-codons 594/596). Although clinical, pathologic, and molecular features of V600EBRAFmutated metastatic colorectal cancer (mCRC) are well known, limited data are available from the two other classes. Experimental Design: Data from 117 patients with BRAF (92 class 1, 12 class 2, and 13 class 3)-mutated mCRC were collected. A total of 540 BRAF wt mCRCs were included as control. IHC profiling was performed to determine the consensus molecular subtypes (CMS), cytokeratin 7/20 profiles, tumor-infiltrating lymphocyte infiltration, and BM1/BM2 categorization. Overall survival (OS) and progression-free survival were evaluated by Kaplan-Meier and log-rank test. Results: Class 3 BRAF-mutated mCRC was more frequently left sided (P = 0.0028), pN0 (P = 0.0159), and without peritoneal metastases (P = 0.0176) compared with class 1, whereas class 2 cases were similar to class 1. Hazard ratio for OS, as compared with BRAF wt, was 2.38 [95% confidence interval (CI), 1.61-3.54] for class 1, 1.90 (95% CI, 0.85-4.26) for class 2, and 0.93 (95% CI, 0.51-1.69) for class 3 (P < 0.0001). Class 2 and 3 tumors were all assigned to CMS2-3. A higher median CD3/CD8-positive lymphocyte infiltration was observed in BRAF-mutated class 2 (P = 0.033) compared with class 3 cases. Conclusions: For the first time, different clinical and pathologic features and outcome data were reported according to the three BRAF mutation classes in mCRC. Specific targeted treatment strategies should be identified in the near future for such patients.
25
13
3954
3961
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization / Schirripa, M.; Biason, P.; Lonardi, S.; Pella, N.; Simona Pino, M.; Urbano, F.; Antoniotti, C.; Cremolini, C.; Corallo, S.; Pietrantonio, F.; Gelsomino, F.; Cascinu, S.; Orlandi, A.; Munari, G.; Malapelle, U.; Saggio, S.; Fontanini, G.; Rugge, M.; Mescoli, C.; Lazzi, S.; Bonetti, L. R.; Lanza, G.; Dei Tos, A. P.; De Maglio, G.; Martini, M.; Bergamo, F.; Zagonel, V.; Loupakis, F.; Fassan, M.. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 25:13(2019), pp. 3954-3961. [10.1158/1078-0432.CCR-19-0311]
Schirripa, M.; Biason, P.; Lonardi, S.; Pella, N.; Simona Pino, M.; Urbano, F.; Antoniotti, C.; Cremolini, C.; Corallo, S.; Pietrantonio, F.; Gelsomino, F.; Cascinu, S.; Orlandi, A.; Munari, G.; Malapelle, U.; Saggio, S.; Fontanini, G.; Rugge, M.; Mescoli, C.; Lazzi, S.; Bonetti, L. R.; Lanza, G.; Dei Tos, A. P.; De Maglio, G.; Martini, M.; Bergamo, F.; Zagonel, V.; Loupakis, F.; Fassan, M.
File in questo prodotto:
File Dimensione Formato  
3954.full.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 488.4 kB
Formato Adobe PDF
488.4 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1222213
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 31
social impact